The PRoFESS trial: future impact on secondary stroke prevention

References

• Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA284, 2901–2906 (2000).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology64(5), 817–820 (2005).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarcton, and stroke in high risk patients. Br. Med. J.524, 71–86 (2002).
   Google Scholar
• Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci.143, 1–13 (1996).
   PubMed Web of Science ®Google Scholar
• The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet367, 1665–1673 (2006).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348, 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Diener H, Bogousslavsky J, Brass LM et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc. Dis.17, 253–261 (2004).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354(16), 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(Suppl. 3), S483–S512 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. Br. Med. J.324, 699–702 (2002).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke36(6), 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Schrader J, Lüders S, Kulschewski A et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke34, 1699–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Diener HC, Sacco R, Yusuf S. For the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens and telmisartan vs placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes (PRoFESS) trial. Cerebrovasc. Dis.23, 368–380 (2007).
   PubMed Web of Science ®Google Scholar
• Fisher LD, Gent M, Buller HR. Active control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin and placebo. Am. Heart J.141, 26–32 (2001).
   PubMed Web of Science ®Google Scholar
• Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology62, 569–573 (2004).
   PubMed Web of Science ®Google Scholar
• Weimar C, Roth MP, Zillessen G et al. Complications following acute ischemic stroke. Eur. Neurol.48>, 133–140 (2002).
   PubMed Web of Science ®Google Scholar
• Thone-Reineke C, Zimmermann M, Neumann C et al. Are angiotensin receptor blockers neuroprotective? Curr. Hypertens. Rep.6(4), 257–266 (2004).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomised trials. Stroke31, 1779–1784 (2000).
   PubMed Web of Science ®Google Scholar
• Hardie K, Jamrozik K, Hankey GJ, Broadhurst RJ, Anderson C. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc. Dis.19(3), 179–185 (2005).
   PubMed Web of Science ®Google Scholar
• Gent M, Blakely JA, Easton JD et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet1(8649), 1215–1220 (1989).
   PubMed Web of Science ®Google Scholar
• Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke. N. Engl. J. Med.321, 501–507 (1989).
   PubMed Web of Science ®Google Scholar